The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the first new type of medication in decades that alleviates symptoms without common side effects. Available by late October, the drug will cost $1,850 monthly before insurance and rebates.
Related Posts
Stock market today: BSE Sensex crashes 800 points; Nifty50 tests 23,200
- staff
- January 13, 2025
- 0
Stock market today: BSE Sensex and Nifty50, the Indian equity benchmark indices, crashed in trade on Monday morning. While BSE Sensex went below 76,600, Nifty50 […]
Pixxel wins Nasa contract for hyperspectral Earth observation tech
Pixxel, a space startup based in Bengaluru, has been awarded a contract by Nasa as part of the $476 million Commercial SmallSat Data Acquisition Program. […]
Bank credit aligning with deposits growth, no stress
- staff
- February 1, 2025
- 0
Bank loans continue to show no stress at the macro level, remaining well below the long-term trend as a percentage of GDP. By Dec 2024, […]